

**London - Surrey Borders Research Ethics Committee**

Equinox House  
City Link  
Nottingham  
NG2 4LA

13 April 2022

Prof Anthony Gordon  
UK Chief Investigator  
Imperial College London  
11th floor Intensive Care Unit  
Charing Cross Hospital  
Fulham Palace Road  
w6 8rf

Dear Prof Gordon

**Study title:** Randomized, Embedded, Multifactorial, Adaptive Platform  
trial for Community-Acquired Pneumonia  
**REC reference:** 18/LO/0660  
**EudraCT number:** 2015-002340-14  
**Amendment number:** AM034  
**Amendment date:** 02 March 2022  
**IRAS project ID:** 237150

The above amendment was reviewed on 24 March 2022 by the Sub-Committee in correspondence.

**Ethical opinion**

The members of the Committee taking part in the review gave a favourable ethical opinion of the amendment on the basis described in the notice of amendment form and supporting documentation.

**Approved documents**

The documents reviewed and approved at the meeting were:

<i>Document</i>	<i>Version</i>	<i>Date</i>
Annex 1: Clinical Trial Application Form [MhraProductsForm_REMAP-CAP AM034 020322]	v1.0	02 March 2022
Completed Amendment Tool		02 March 2022
Confirmation of Clinical Trial Authorisation from MHRA and relevant correspondence [MHRA approval]		24 March 2022
Cover Letter [REMAP-CAP AM034 cover letter 02.03.22]	v1.0	02 March 2022

## **Membership of the Committee**

The members of the Committee who took part in the review are listed on the attached sheet.

## **Working with NHS Care Organisations**

Sponsors should ensure that they notify the R&D office for the relevant NHS care organisation of this amendment in line with the terms detailed in the categorisation email issued by the lead nation for the study.

## **Amendments related to COVID-19**

We will update your research summary for the above study on the research summaries section of our website. During this public health emergency, it is vital that everyone can promptly identify all relevant research related to COVID-19 that is taking place globally. If you have not already done so, please register your study on a public registry as soon as possible and provide the HRA with the registration detail, which will be posted alongside other information relating to your project.

## **Statement of compliance**

This Committee is recognised by the United Kingdom Ethics Committee Authority under the Medicines for Human Use (Clinical Trials) Regulations 2004, and is authorised to carry out the ethical review of clinical trials of investigational medicinal products.

The Committee is fully compliant with the Regulations as they relate to ethics committees and the conditions and principles of good clinical practice.

The Committee is constituted in accordance with the Governance Arrangements for Research Ethics Committees and complies fully with the Standard Operating Procedures for Research Ethics Committees in the UK.

## **HRA Learning**

We are pleased to welcome researchers and research staff to our HRA Learning Events and online learning opportunities– see details at: <https://www.hra.nhs.uk/planning-and-improving-research/learning/>

<b>IRAS Project ID - 237150:</b>	<b>Please quote this number on all correspondence</b>
----------------------------------	-------------------------------------------------------

Yours sincerely

**Mr Tobias Davis**  
**Chair**

E-mail: [surreyborders.rec@hra.nhs.uk](mailto:surreyborders.rec@hra.nhs.uk)

*Enclosures:*                      *List of names and professions of members who took part in the review*

*Copy to:*                          *Dr Farah Al-Beidh*

**London - Surrey Borders Research Ethics Committee**

**Attendance at Sub-Committee of the REC meeting on 24 March 2022**

**Committee Members:**

<i>Name</i>	<i>Profession</i>	<i>Present</i>	<i>Notes</i>
Mr Tobias Davis	Medical Device Expert	Yes	
Miss Holly Shrimpton	Head of Healthcare	Yes	